Skip to main content
NCBI home page
Bulletin of the World Health Organization logoLink to Bulletin of the World Health Organization
. 1990;68(Suppl):38–41.

Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks.

D Stürchler 1, G Zimmer 1, R Berger 1, H Etlinger 1, M Fernex 1, H Matile 1, M Just 1
PMCID: PMC2393033  PMID: 2094589

Abstract

Adults with no known immunity to sporozoites received, i.m., at weeks 0 and 8 two single 200 micrograms doses of a peptide Plasmodium falciparum sporozoite vaccine conjugated to tetanus toxoid ((NANP)3-TT) plus placebo (group 1) or interferon-alpha (IFN-alpha) (group 2) and were followed for antibody responses at weeks 4, 12 and 40. Peak antibody responses were observed at week 12. At week 40, a greater than or equal to 4-fold increase in antibody titre to sporozoites in IFA, or to (NANP)50 in ELISA was still detectable in 6 of 12 (50%) volunteers in group 1 and in 16 of 25 (64%) in group 2. Peak antibody titres in IFA and ELISA decreased with a rate of 0.8% and 0.5% per week, respectively.

Full text

PDF
38

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ballou W. R., Hoffman S. L., Sherwood J. A., Hollingdale M. R., Neva F. A., Hockmeyer W. T., Gordon D. M., Schneider I., Wirtz R. A., Young J. F. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet. 1987 Jun 6;1(8545):1277–1281. doi: 10.1016/s0140-6736(87)90540-x. [DOI] [PubMed] [Google Scholar]
  2. Dame J. B., Williams J. L., McCutchan T. F., Weber J. L., Wirtz R. A., Hockmeyer W. T., Maloy W. L., Haynes J. D., Schneider I., Roberts D. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite Plasmodium falciparum. Science. 1984 Aug 10;225(4662):593–599. doi: 10.1126/science.6204383. [DOI] [PubMed] [Google Scholar]
  3. Etlinger H. M., Felix A. M., Gillessen D., Heimer E. P., Just M., Pink J. R., Sinigaglia F., Stürchler D., Takacs B., Trzeciak A. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum. J Immunol. 1988 Jan 15;140(2):626–633. [PubMed] [Google Scholar]
  4. Levine M. M., Herrington D., Clyde D., Murphy J., Davis J., Nussenzweig R., Nardin E., Felix A., Heimer E., Gillesen D. Malaria vaccines: experience with sporozoite vaccines against falciparum malaria. Southeast Asian J Trop Med Public Health. 1988 Sep;19(3):369–374. [PubMed] [Google Scholar]
  5. Pang L. W., Limsomwong N., Karwacki J., Webster H. K. Circumsporozoite antibodies and falciparum malaria incidence in children living in a malaria endemic area. Bull World Health Organ. 1988;66(3):359–363. [PMC free article] [PubMed] [Google Scholar]
  6. Webster H. K., Brown A. E., Chuenchitra C., Permpanich B., Pipithkul J. Characterization of antibodies to sporozoites in Plasmodium falciparum malaria and correlation with protection. J Clin Microbiol. 1988 May;26(5):923–927. doi: 10.1128/jcm.26.5.923-927.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Webster H. K., Diggs C. L., Ballou W. R., Chulay J. D. Vaccines for human malaria: epidemiological and immunological perspectives. Southeast Asian J Trop Med Public Health. 1988 Sep;19(3):375–389. [PubMed] [Google Scholar]
  8. del Portillo H. A., Nussenzweig R. S., Enea V. Circumsporozoite gene of a Plasmodium falciparum strain from Thailand. Mol Biochem Parasitol. 1987 Jul;24(3):289–294. doi: 10.1016/0166-6851(87)90161-7. [DOI] [PubMed] [Google Scholar]

Articles from Bulletin of the World Health Organization are provided here courtesy of World Health Organization

RESOURCES